Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and Advanced Non-Small-Cell Lung Cancer Patients with Chronic Infection
Conclusions: The PD-1 inhibitor showed an acceptable toxicity profile and moderate efficacy on NSCLC patients with chronic infection, but still has the potential to increase the incidence of hepatitis.
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Anemia | Avastin | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Hepatitis | Hepatitis B | Hepatitis C | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Syphilis | Toxicology